Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ANTH's Cash to Debt is ranked higher than
86% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. ANTH: No Debt )
ANTH' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -142.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -387.13
ANTH's ROE (%) is ranked lower than
52% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. ANTH: -387.13 )
ANTH' s 10-Year ROE (%) Range
Min: -582.71   Max: -179.7
Current: -387.13

-582.71
-179.7
ROA (%) -129.80
ANTH's ROA (%) is ranked higher than
51% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. ANTH: -129.80 )
ANTH' s 10-Year ROA (%) Range
Min: -254.43   Max: -94.5
Current: -129.8

-254.43
-94.5
ROC (Joel Greenblatt) (%) -4485.97
ANTH's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. ANTH: -4485.97 )
ANTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238386.67   Max: -2879.41
Current: -4485.97

-238386.67
-2879.41
EBITDA Growth (3Y)(%) -59.60
ANTH's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ANTH: -59.60 )
ANTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -52
Current: -59.6

EPS Growth (3Y)(%) -59.40
ANTH's EPS Growth (3Y)(%) is ranked higher than
53% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ANTH: -59.40 )
ANTH' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -50.7
Current: -59.4

» ANTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ANTH Guru Trades in Q1 2014

Jim Simons 97,400 sh (+46.03%)
Louis Moore Bacon 200,000 sh (-11.03%)
» More
Q2 2014

ANTH Guru Trades in Q2 2014

Jim Simons 124,899 sh (+28.23%)
Louis Moore Bacon 200,000 sh (unchged)
» More
Q3 2014

ANTH Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
Jim Simons 26,700 sh (-78.62%)
» More
Q4 2014

ANTH Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -4.67
ANTH's EV-to-EBIT is ranked higher than
54% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ANTH: -4.67 )
ANTH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.67

Current Ratio 0.53
ANTH's Current Ratio is ranked lower than
52% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ANTH: 0.53 )
ANTH' s 10-Year Current Ratio Range
Min: 0.21   Max: 8.15
Current: 0.53

0.21
8.15
Quick Ratio 0.53
ANTH's Quick Ratio is ranked lower than
51% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. ANTH: 0.53 )
ANTH' s 10-Year Quick Ratio Range
Min: 0.21   Max: 8.15
Current: 0.53

0.21
8.15

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -21.70
ANTH's Earnings Yield (Greenblatt) is ranked lower than
57% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ANTH: -21.70 )
ANTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -112.9   Max: 0
Current: -21.7

-112.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:6TA1.Germany,
Anthera Pharmaceuticals Inc was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for ANTH

Headlines

Articles On GuruFocus.com
comment on ANTH Mar 02 2013 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 12 2010 
Weekly CFO Buys Highlight: Inuvo Inc., Heelys Inc., Peregrine Pharmaceuticals Inc., Anthera Pharmace Sep 26 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 12 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera... Apr 22 2015
The Zacks Analyst Blog Highlights: Pfizer, Pharmacyclics, Geron, Anthera Pharmaceuticals and Cytori... Apr 16 2015
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock Mar 23 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 20 2015
ANTHERA PHARMACEUTICALS INC Financials Mar 20 2015
Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for... Mar 19 2015
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 18 2015
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 17 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 16 2015
Anthera reports 4Q loss Mar 16 2015
Anthera reports 4Q loss Mar 16 2015
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod... Mar 16 2015
Anthera Pharmaceuticals Reports 2014 Fourth Quarter and Fiscal Year Financial Results, Operational... Mar 16 2015
Anthera Pharmaceuticals to Present at Cowen & Co. Healthcare Conference Feb 19 2015
Strength Seen in Anthera (ANTH): Stock Soars 25% - Tale of the Tape Feb 11 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 11 2015
Anthera Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Feb 10 2015
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod... Feb 10 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 28 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK